Patents Assigned to Pharming
  • Method of preparing very slightly soluble drug with solid dosage form
    Patent number: 10137126
    Abstract: A method of preparing a very slightly soluble drug with solid composition includes the following steps: (a) adding a very slightly soluble drug into an organic solvent and polysorbate to form a first solution; (b) adding the first solution into a second solution and a pharmaceutically acceptable excipient, wherein the second solution comprises water or SLS, and a volume ratio of the first solution and the second solution is between 8:1 and 1:1; and (c) drying and compressing the mixture in step (b) to form a very slightly soluble drug with solid composition.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: November 27, 2018
    Assignee: YUNG SHIN PHARM. IND. CO., LTD.
    Inventors: Fang-Yu Lee, Fu-Yung Lin
  • PROTEIN COMPLEX BY USE OF A SPECIFIC SITE OF AN IMMUNOGLOBULIN FRAGMENT FOR LINKAGE
    Publication number: 20180326013
    Abstract: Provided is a complex composition, of which positional isomers are minimized by using a N-terminus of an immunoglobulin Fc region as a binding site when the immunoglobulin Fc region is used as a carrier. Also provided are a protein complex which is prepared by N-terminal-specific binding of immunoglobulin Fc region, thereby prolonging blood half-life of the physiologically active polypeptide, maintaining in vivo potency at a high level, and having no risk of immune responses, a preparation method thereof, and a pharmaceutical composition including the same for improving in vivo duration and stability of the physiologically active polypeptide. The protein complex prepared by the present invention may be usefully applied to the development of long-acting formulations of various physiologically active polypeptide drugs.
    Type: Application
    Filed: September 26, 2016
    Publication date: November 15, 2018
    Applicant: HANMI PHARM. CO., LTD
    Inventors: Dae Jin KIM, Jong Soo LEE, Young Jin PARK, Sung Hee HONG, Sung Min BAE, Se Chang KWON
  • NOVEL PROCESS FOR PREPARING THIENOPYRIMIDINE COMPOUND AND INTERMEDIATES USED THEREIN
    Publication number: 20180312520
    Abstract: The present invention relates to a novel method for preparing thienopyrimidine compound having an activity of selectively inhibiting tyrosine kinase, specifically the mutant epidermal growth factor receptor tyrosine kinase; and a novel intermediate used therein. According to the method of the present invention, the industrial mass-production of the compound of Formula 1, which is useful as a therapeutic agent for non-small cell lung cancer induced by the mutant epidermal growth factor receptor tyrosine kinase, can be implemented more conveniently and efficiently than the conventional technology.
    Type: Application
    Filed: October 31, 2016
    Publication date: November 1, 2018
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Wook JANG, Young Ho MOON, Tae Hee HA, Kwee Hyun SUH
  • LONG-ACTING CONJUGATE OF TRIPLE GLUCAGON/GLP-1/GIP RECEPTOR AGONIST
    Publication number: 20180311315
    Abstract: The present invention relates to a long-acting conjugate of a triple agonist having activities to all of glucagon, GLP-1, and GIP receptors and uses thereof.
    Type: Application
    Filed: June 29, 2018
    Publication date: November 1, 2018
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Euh Lim OH, Jong Suk LEE, Young Jin PARK, Chang Ki LIM, Sung Youb JUNG, Se Chang KWON
  • METHOD FOR PREPARING THIENOPYRIMIDINE COMPOUND AND INTERMEDIATES USED THEREIN
    Publication number: 20180312521
    Abstract: A method for preparing a thienopyrimidine compound of Formula 1, which is a selective inhibitor of tyrosine kinase activity, in particular, of mutant epidermal growth factor receptor tyrosine kinase. Intermediates used in the method are provided.
    Type: Application
    Filed: July 2, 2018
    Publication date: November 1, 2018
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Jong Ouk BAEK, Jae Hyuk JUNG, Ho Seok KIM, Tae Hee HA, Kwee Hyun SUH
  • Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase
    Patent number: 10112954
    Abstract: The present invention relates to a novel bicyclic heteroaryl derivative, a pharmaceutically acceptable salt thereof, a hydrate thereof, and a solvate thereof having an improved inhibitory activity for protein kinases, and a pharmaceutical composition for preventing or treating an abnormal cell growth disorder comprising same as an active ingredient.
    Type: Grant
    Filed: January 28, 2011
    Date of Patent: October 30, 2018
    Assignees: HANMI PHARM. CO., LTD., HANMI SCIENCE CO., LTD.
    Inventors: Seung Hyun Jung, Young Hee Jung, Wha Il Choi, Jung Beom Son, Eun Ju Jeon, In Ho Yang, Tae Hun Song, Mi Kyoung Lee, Myoung Sil Ko, Young Gil Ahn, Maeng Sup Kim, Young Jin Ham, Tae Bo Sim, Hwan Geun Choi, Jung Mi Hah, Dong-sik Park, Hwan Kim
  • METHOD OF INSULIN PRODUCTION
    Publication number: 20180291077
    Abstract: The present invention relates to a method of preparing insulin from proinsulin comprising converting high-concentration proinsulin into insulin by enzymatic cleavage, a method of purifying insulin, and insulin prepared therefrom.
    Type: Application
    Filed: September 23, 2016
    Publication date: October 11, 2018
    Applicant: HANMI PHARM. CO., LTD
    Inventors: Seong Ho CHOI, Dae Jin KIM, Jin Young KIM, Sang Yun KIM, In Young CHOI, Se Chang KWON
  • INSULIN ANALOGS AND USE THEREOF
    Publication number: 20180282388
    Abstract: An insulin analog with an improved in vitro effect compared with native insulin, a nucleic acid encoding the same, an expression vector including the nucleic acid, a transformant introduced with the expression vector, a method of producing the insulin analog from the transformant, a pharmaceutical composition for treating diabetes containing the insulin analog as an active ingredient, and a method for treating diabetes using the insulin analog or the pharmaceutical composition.
    Type: Application
    Filed: May 25, 2018
    Publication date: October 4, 2018
    Applicant: HANMI PHARM. CO., LTD
    Inventors: Jin Young KIM, Euh Lim OH, Jong Soo LEE, Hyung Kyu LIM, In Young CHOI, Se Chang KWON
  • A PROTEIN CONJUGATE COMPRISING MULTIPLE PHYSIOLOGICALLY ACTIVE POLYPEPTIDES AND AN IMMUNOGLOBULIN FC REGION
    Publication number: 20180271995
    Abstract: The present invention relates to a physiologically active polypeptide conjugate comprising multiple physiologically active polypeptides and immunoglobulin Fc regions, use thereof, and a preparation method thereof.
    Type: Application
    Filed: September 26, 2016
    Publication date: September 27, 2018
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Jong Soo LEE, Seong Ho CHOI, Jae Hyuk CHOI, Sang Yun KIM, Sung Youb JUNG, Se Chang KWON
  • Sulfamate derivative compounds for use in treating or alleviating pain
    Patent number: 10081615
    Abstract: The present invention relates to sulfamate derivative compounds and a composition for treating and/or alleviating pain containing the sulfamate derivative compounds or a pharmaceutically acceptable salt thereof as an active ingredient. More specifically the present invention relates to a pharmaceutical composition for treating or alleviating pain containing a sulfamate derivative compound and/or a pharmaceutically acceptable salt thereof as an active ingredient. Furthermore, the present invention relates to a method for treatment or alleviation of pain comprising administering a sulfamate derivative compound in a pharmaceutically effective amount to a subject in need of treatment or alleviation of pain.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: September 25, 2018
    Assignee: Bio-Pharm Solutions Co., Ltd.
    Inventor: Yong Moon Choi
  • NOVEL INSULIN ANALOG AND USE THEREOF
    Publication number: 20180256731
    Abstract: An insulin analog has a reduced insulin titer and a reduced insulin receptor binding affinity compared to the native form for the purpose of increasing the blood half-life of insulin. A conjugate is prepared by linking the insulin analog and a carrier. A long-acting formulation includes the conjugate.
    Type: Application
    Filed: May 18, 2018
    Publication date: September 13, 2018
    Applicant: HANMI PHARM. CO., LTD
    Inventors: Sang Youn Hwang, Yong Ho Huh, Jin Young Kim, Sung Hee Hong, In Young Choi, Sung Youb Jung, Se Chang Kwon, Dae Jin Kim, Hyun Uk Kim, Myung Hyun Jang, Seung Su Kim
  • Method for preparing gadobutrol
    Patent number: 10065933
    Abstract: The present disclosure relates to a novel method for preparing high-purity gadobutrol. The present disclosure can be easily applied to a large scale production because purity of intermediate can be managed via simple and mild process and accordingly, high-purity or ultra high-purity gadobutrol that has higher purity than previous gadobutrol can be prepared in high yield therethrough.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: September 4, 2018
    Assignee: ST PHARM CO., LTD.
    Inventors: Geun Jho Lim, Sun Ki Chang, Chang Ho Byeon, Hoe Jin Yoon, Moon Soo Kim
  • AN ORAL PHARMACEUTICAL FORMULATION COMPRISING SUSTAINED-RELEASE GRANULES CONTAINING TAMSULOSIN HYDROCHLORIDE
    Publication number: 20180235913
    Abstract: An oral pharmaceutical formulation containing sustained-release granules including tamsulosin hydrochloride and a method of preparing the oral pharmaceutical formulation are provided. In the oral pharmaceutical formulation, the sustained-release granules includes about 10 parts to about 300 parts by weight of polyvinyl acetate, about 5 parts to about 250 parts by weight of hydroxypropyl methylcellulose, and about 1 part to about 450 parts by weight of a diluting agent with respect to 1 part by weight of tamsulosin hydrochloride, and a weight ratio of the sustained-release granules with respect to 1 part by weight of tamsulosin hydrochloride is about 360 to 495 parts by weight.
    Type: Application
    Filed: February 16, 2016
    Publication date: August 23, 2018
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Hyung Seo KIM, Young Keun CHOI, Jung Hyun CHO, Jin Cheul KIM, Yong Il KIM, Jae Hyun PARK, Jong Soo WOO
  • Site-specific insulin conjugate
    Patent number: 10046061
    Abstract: Provided are an insulin conjugate having improved insulin receptor binding affinity and increased activity, in which a non-peptidyl polymer and an immunoglobulin Fc region are site-specifically linked to an amino acid residue of the insulin beta chain excluding the N-terminus thereof via a covalent bond, a long-acting formulation including the same, and a preparation method thereof. The insulin conjugate of the present invention is used to provide an insulin formulation which exhibits a remarkably increased in vivo activity of the peptide.
    Type: Grant
    Filed: February 26, 2014
    Date of Patent: August 14, 2018
    Assignee: HANMI PHARM. CO., LTD
    Inventors: Myung Hyun Jang, Dae Jin Kim, Sang Youn Hwang, Hyun Uk Kim, Sung Youb Jung, Se Chang Kwon
  • Nicotine-containing liquid formulations and uses thereof
    Patent number: 10045976
    Abstract: Nicotine liquid formulations and their use in therapy, for instance, in nicotine replacement therapy are described. More specifically, the technology relates to liquid nicotine formulations comprising nicotine, one or more diol and/or triol, and a sugar alcohol, which may be used as sprays for administration through the oral cavity, such as the palate.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: August 14, 2018
    Assignee: EURO-PHARM INTERNATIONAL CANADA INC.
    Inventors: Rolando Fusco, Leonardo Calderone
  • Method for preparing thienopyrimidine compound and intermediates used therein
    Patent number: 10040801
    Abstract: The present invention provides a novel method for preparing a thienopyrimidine compound of Formula 1, which is a selective inhibitor of tyrosine kinase activity, in particular, of mutant epidermal growth factor receptor tyrosine kinase, and novel intermediates used in the method.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: August 7, 2018
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Jong Ouk Baek, Jae Hyuk Jung, Ho Seok Kim, Tae Hee Ha, Kwee Hyun Suh
  • COMBINATION OF CROSS-LINKED HYALURONIC ACIDS AND METHOD OF PREPARING THE SAME
    Publication number: 20180215840
    Abstract: Provided are a method of preparing a cross-linked hyaluronic acid having an elasticity of about 50 to about 200 Pa and a viscosity of about 20 to about 100 Pa, including cross-linking hyaluronic acid with an epoxy-based cross-linking agent having at least two epoxy functional groups in an ethanol-containing aqueous alkaline; a method of preparing a cross-linked hyaluronic acid having an elasticity of about 400 to about 800 Pa and a viscosity of about 40 to about 100 Pa, including cross-linking the same cross-linked hyaluronic acid with the same epoxy-based cross-linking agent in an aqueous alkaline solution; and a combination of the cross-linked hyaluronic acids one having an elasticity of about 50 to about 200 Pa and a viscosity of about 20 to about 100 Pa and the other having an elasticity of about 400 to about 800 Pa and a viscosity of about 40 to about 100 Pa.
    Type: Application
    Filed: June 1, 2016
    Publication date: August 2, 2018
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Sung Chul CHOI, Hyun Il KIM, Ki Young YANG, Hyo Seung PARK, Back Ho LEE
  • Solid pharmaceutical composition comprising amlodipine and losartan
    Patent number: 10034862
    Abstract: The present invention provides a pharmaceutical composition for the prevention or treatment of cardiovascular disorders containing losartan or a pharmaceutically acceptable salt thereof; amlodipine or a pharmaceutically acceptable salt thereof; a disintegrant; and a coating agent. The composition of the present invention, which has the best combination and optimum ratio of a disintegrant to a coating agent, shows sufficient strength and high dissolution rates under various pH environments, and thus, it is useful for the preparation of an excellent solid formulation exhibiting improved drug delivery efficiency and storage stability.
    Type: Grant
    Filed: September 1, 2015
    Date of Patent: July 31, 2018
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Leedong Roh, Ho Taek Im, Young Su Yoon, Yong Il Kim, Jae Hyun Park, Jong Soo Woo
  • Vascular endothelial growth factor fusion protein
    Patent number: 10023627
    Abstract: The present invention relates to a fusion protein binding to a vascular endothelial growth factor (VEGFR) and/or a placental growth factor (PIGF). The fusion protein of the present invention comprises (a) a Fc domain of IgG1, wherein two heavy chains are linked by disulfide bond, and (b) four immunoglobulin domain2s of the VEGFR1, wherein two immunoglobulin domain2s are sequentially fused to each heavy chain of the Fc domain of (a). The present fusion protein has excellent activities of inhibiting cell migration and cell invasion, and has highly enhanced growth inhibition effects to various carcinomas and fibroblasts. Therefore, The fusion protein of the present invention can be used in the preparation of an agent for treating cancers or ocular diseases.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: July 17, 2018
    Assignee: KOREA PRIME PHARM CO., LTD.
    Inventors: Daeik Kim, Inra Seo
  • Insulin analogs and use thereof
    Patent number: 10017557
    Abstract: Insulin analog with an improved in vitro effect compared with native insulin, a nucleic acid encoding the same, an expression vector including the nucleic acid, a transformant introduced with the expression vector, a method of producing the insulin analog from the transformant, a pharmaceutical composition for treating diabetes containing the insulin analog as an active ingredient, and a method for treating diabetes using the insulin analog or the pharmaceutical composition are described.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: July 10, 2018
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Jin Young Kim, Euh Lim Oh, Jong Soo Lee, Hyung Kyu Lim, In Young Choi, Se Chang Kwon